liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Microscopic colitis: Current status, present and future challenges Statements of the European Microscopic Colitis Group
Linköping University, Department of Clinical and Experimental Medicine, Gastroenterology and Hepatology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Endocrinology and Gastroenterology UHL.
University Hospital, Dresden, Germany.
Örebro University Hospital, Sweden and University of Örebro, Sweden .
Regional Hospital Silkeborg, Denmark .
Show others and affiliations
2012 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 6, no 9, 932-945 p.Article in journal (Refereed) Published
Abstract [en]

Microscopic colitis (MC) is an inflammatory bowel disease presenting with chronic, non-bloody watery diarrhoea and few or no endoscopic abnormalities. The histological examination reveals mainly two subtypes of MC, lymphocytic or collagenous colitis. Despite the fact that the incidence in MC has been rising over the last decades, research has been sparse and our knowledge about MC remains limited. Specialists in the field have initiated the European Microscopic Colitis Group (EMCG) with the primary goal to create awareness on MC. The EMCG is furthermore a forum with the intention to promote clinical and basic research. In this article statements and comments are given that all members of the EMCG have considered being of importance for a better understanding of MC. The paper focuses on the newest updates in epidemiology, symptoms and diagnostic criteria, pathophysiology and highlights some unsolved problems. Moreover, a new treatment algorithm is proposed on the basis of new evidence from well-designed, randomized control trials.

Place, publisher, year, edition, pages
Elsevier , 2012. Vol. 6, no 9, 932-945 p.
Keyword [en]
Microscopic colitis, Collagenous colitis, Lymphocytic colitis, Budesonide
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-85622DOI: 10.1016/j.crohns.2012.05.014ISI: 000309990400009OAI: oai:DiVA.org:liu-85622DiVA: diva2:572067
Note

Funding Agencies|Tillots Pharma||Falk Pharma||Tillotts Pharma||Ferring||MSD||Astra-Zeneca||Falk Foundation, Germany||MEDA, Sweden||

Available from: 2012-11-26 Created: 2012-11-26 Last updated: 2017-12-07

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Münch, AndreasHjortswang, HenrikStröm, Magnus

Search in DiVA

By author/editor
Münch, AndreasHjortswang, HenrikStröm, Magnus
By organisation
Gastroenterology and HepatologyFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
In the same journal
Journal of Crohn's & Colitis
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 134 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf